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Abstract 
Increases in expression of ADAM10 and ADAM17 genes and proteins have been evaluated, but not 
validated as cancer biomarkers. Specific enzyme activities better reflect enzyme cellular functions, and 
might be better biomarkers than enzyme genes or proteins. However, no high throughput assay is 
available to test this possibility. Recent studies have developed the high throughput real-time proteolytic 
activity matrix analysis (PrAMA) that integrates the enzymatic processing of multiple enzyme substrates 
with mathematical-modeling computation. The original PrAMA measures with significant accuracy the 
activities of individual metalloproteinases expressed on live cells. To make the biomarker assay usable in 
clinical practice, we modified PrAMA by testing enzymatic activities in cell and tissue lysates 
supplemented with broad-spectrum non-MP enzyme inhibitors, and by maximizing the assay specificity 
using systematic mathematical-modeling analyses. The modified PrAMA accurately measured the 
absence and decreases of ADAM10 sheddase activity (ADAM10sa) and ADAM17sa in ADAM10-/- and 
ADAM17-/- mouse embryonic fibroblasts (MEFs), and ADAM10- and ADAM17-siRNA transfected 
human cancer cells, respectively. It also measured the restoration and inhibition of ADAM10sa in 
ADAM10-cDNA-transfected ADAM10-/- MEFs and GI254023X-treated human cancer cell and tissue 
lysates, respectively. Additionally, the modified PrAMA simultaneously quantified with significant 
accuracy ADAM10sa and ADAM17sa in multiple human tumor specimens, and showed the essential 
characteristics of a robust high throughput multiplex assay that could be broadly used in biomarker 
studies. Selectively measuring specific enzyme activities, this new clinically applicable assay is potentially 
superior to the standard protein- and gene-expression assays that do not distinguish active and inactive 
enzyme forms. 
Key words: Cancer biomarker, Sheddase activity, ADAM10, ADAM17, Fluorogenic peptide substrates, Proteolytic activity 
matrix analysis, Cell lysate, Tissues, lysate, Gene knockout, Gene silence, Gene restoration, Protease inhibitors 
Introduction 
ADAM10 and ADAM17 are transmembrane 
metallopeptidases of ADAM (A Disintegrin And 
Metalloprotease) gene-superfamily that have 
important roles in normal cell functions and 
pathogenesis of inflammatory, cardiovascular, skin 
and malignant diseases [1]. Primary functions of 
ADAM10 and ADAM17 are proteolytic cleavage on 
the cell surface and release (shedding) of functional 
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extracellular domains (ectodomains) of membrane- 
anchored (transmembrane) proteins that mediate 
epidermal growth and inflammation.  
ADAM17, also referred to as tumor necrosis 
factor alpha converting enzyme (TACE) and CD156q, 
is a major sheddase of the epidermal growth factors 
(EGFs) TGF-α, amphiregulin (AR) and 
heparin-binding EGF (HB-EGF), and of the central 
proinflammatory and immunoregulatory cytokine 
tumor necrosis factor alpha (TNF) [1-5]. ADAM17 also 
sheds several cell-adhesion molecules, TNF 
superfamily receptors, cytokines and chemokines 
[5-12]. Due to the enzyme activity-generated 
biologically active molecules, ADAM17 mediates vital 
functions such as development and modeling of 
tissues and organs, wound healing, inflammation and 
regulation of immune responses [5, 7, 12, 13]. 
ADAM17 knockout mice show perinatal lethality and 
defects similar to those found in EGF receptor or 
ligand deficient mice, including defective 
development of the eyelids, hair, whiskers, heart 
valves, and mammary glands [1]. ADAM17-knockout 
mice also display impaired thymic epithelium 
formation and T-cell development, as well as 
defective B-cell follicle formation and B-cell 
maturation, and thus resemble to lymphotoxin- and 
TNF-signaling deficient mice [1]. 
Complementary and partially overlapping with 
ADAM17, ADAM10, also known as CDw156, CD156c 
and α-secretase, sheds and/or activates the EGF, 
HB-EGF, betacellulin, amyloid precursor protein, and 
several receptors and ligands, including Notch 
receptor and ligands [1, 14-18]. ADAM10 and Notch 
deficient mice have similar phenotypes, including 
defects in embryonal somitogenesis, neurogenesis 
and vasculogenesis, indicating a critical role of 
ADAM10 in Notch signaling [1, 14]. Importantly, 
deregulation of Notch signaling promotes cancer 
progression [19, 20]. These and other published data 
[1, 21] show that ADAM10 and ADAM17 play key 
roles in cancer growth, survival, invasion and 
metastasis, and indicate that they might be important 
cancer biomarkers and therapy targets.  
Increases in expression of ADAM10 and 
ADAM17 genes and/or proteins were frequently 
found in cancer tissues, but were either not robust or 
not associated with poor prognosis and, 
consequently, not validated as cancer biomarkers [1, 
21-34]. Gene- and protein-expression biomarker 
assays measure without distinction both inactive and 
active enzyme forms. However, only specific enzyme 
active forms and their proteolytic activities are 
directly related to enzymatic cellular functions. 
Therefore, the enzyme activities might be better 
cancer biomarkers than the mere quantity of enzyme 
genes or proteins. However, the specific 
enzyme-activity biomarker assays are not currently 
available to test this possibility. 
Clinically applicable enzyme-activity tests 
should be sensitive, specific, quantitative, high 
throughput and able to assess cellular enzymes in 
solid tumors. Previous seminal studies have defined 
the proteolytic activity matrix analysis (PrAMA), 
which integrates the assessment of enzymatic 
processing of multiple fluorogenic peptide substrates 
containing a fluorescence-resonance energy transfer 
(FRET) donor and a quencher, and a 
mathematical-modeling based computation [35]. The 
original PrAMA infers individual enzyme activities of 
MPs, including ADAM10sa and ADAM17sa, in 
mixtures of relatively small varieties of known 
recombinant and unknown natural enzymes 
expressed on live cells. Compared to the otherwise 
non-specific FRET substrate-based enzyme-activity 
assays, PrAMA is more specific, multiplex and 
quantitative. It could be a clinically translatable 
biomarker assay, if it could efficiently measure 
specific cellular enzyme activities in solid tissues.  
To measure the cell-surface enzyme activities in 
solid tissues, three methods could be potentially 
applied. The assay could be performed using isolated 
live cells, purified cell membranes, or soluble extracts 
(lysates). Live cells or cell membranes are obtained 
from fresh tissues, and their isolations are complex, 
laborious and could affect the enzymes of interest. 
Consequently, the enzyme activity assays with such 
isolated live cells or cell membranes are not fully 
accurate and are impractical for clinical use. In 
contrast, the preparation of tissue lysates could be 
effectuated with both fresh and cryopreserved tissues, 
and is simple, rapid and, therefore, practical for 
clinical application. However, tissue lysates contain 
not only cell-membrane bound MPs but also a large 
variety of potent cytoplasmic and nuclear 
“promiscuous” proteases that can process a broad 
spectrum of substrates, including those selected for 
ADAM10 and ADAM17. The activities of intracellular 
proteases could adversely affect PrAMA specificity. 
To specifically measure ADAM10sa and ADAM17sa 
in tissue lysates, the non-MP “promiscuous” 
proteases might need to be inhibited in tested 
specimens. A simple way to do that could be to 
perform the enzyme-activity assessment of the lysates 
in the presence of broad-spectrum non-MP protease 
inhibitors.  
In the present study, we modified PrAMA by 
assessing enzymatic activities in cell and tissue lysates 
supplemented with broad-spectrum non-MP protease 
inhibitors and by analyzing the proteolytic activity 
data by newly applying systematic PrAMA 
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mathematical modeling to maximize specificity of the 
assay for ADAM10sa and ADAM17sa. The modified 
PrAMA measured with a significant accuracy 
ADAM10sa and ADAM17sa in cultured cells and 
tumors, and showed the essential characteristics of a 
robust high throughput multiplex biomarker assay 
that could be applied in practical medicine.  
Materials and Methods  
Reagents 
Seven internally quenched FRET-peptide 
enzyme substrates, including PEPDAB005, 
PEPDAB008, PEPDAB010, PEPDAB011, PEPDAB013, 
PEPDAB014 and PEPDAB022, were purchased from 
BioZyme Inc (Apex, NC). The substrates are based on 
the cleavage sites in specific proteins known to be 
processed by different ADAM family members, and 
are moderately specific [36-38] (Fig. 1A). Trypsin was 
obtained from GIBCO-Life Technologies (Grand 
Island, NY). Recombinant ADAM8, ADAM10, 
ADAM12, ADAM17, MMP1, MMP3, MMP7 and 
MMP9 were obtained from R&D Systems 
(Minneapolis, MN). Phycoerythrin-conjugated mouse 
anti-human ADAM10 and ADAM17, rat anti-mouse 
ADAM10 and corresponding isotype control 
monoclonal antibodies (mAbs) were obtained from 
R&D Systems. Human ADAM10 and ADAM17 
siRNA (pools of three target specific siRNA), control 
(scrambled siRNA), siRNA transfection medium, and 
siRNA transfection reagent were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
Lipofectamine 2000 was purchased from 
ThermoFisher Scientific (Pittsburgh, PA). Control 
(empty) and human ADAM10-cDNA clone plasmids 
were obtained from OriGene (Rockville, MD). 
EDTA-free broad-spectrum non-MP protease 
inhibitor cocktails, including Roche tablets (Roche 
Applied Science, Indianapolis, IN) and ThermoFisher 
Scientific Halt 100 X solution, were utilized to inhibit 
non-MP enzymes in cell and tissue lysates. 
GI254023X, a specific small molecule inhibitor of 
ADAM10sa was obtained from Sigma Aldrich (Sent 
Louis, MO). 10 mM stock solutions of PEPDAB 
substrates and GI254023X were prepared in DMSO 
and stored frozen at -80oC. Enzyme-free, PBS-based, 
GIBCO cell-dissociation solution was purchased from 
ThermoFisher Scientific, and utilized to detach 
cultured adherent cells.  
Cell Lines 
Immortalized wild-type (ADAM10+/-, clone 37) 
and ADAM10 knockout (ADAM10-/-, clone 8T2) 
mouse embryonic fibroblasts (MEFs) were donated by 
Dr. Carl Blobel (Weill Medical College, Cornell 
University, New York, NY) [39], and wild-type 
(ADAM17+/+) and ADAM17 knockout (ADAM17-/-) 
MEFs were provided by Dr. Peter Dempsey 
(University of Colorado Medical School, Aurora, CO) 
[40]. The H441 lung carcinoma cell line was obtained 
from ATCC (Manassas, VA). MEFs were cultured in 
DMEM cell-culture medium supplemented with 10% 
fetal calf serum (FCS), while H441 cells were cultured 
in RPMI-1640 cell-culture medium supplemented 
with 10% FCS (all from GIBCO-Life Technologies). 
The cell lines were maintained in culture by their 
passage at 70% confluency using trypsinization. Five 
passages of these cells were maximally performed, 
after starting these cultures from their frozen stocks 
stored in liquid nitrogen. For experimental use, 
single-cell suspensions of viable cells were obtained 
using the GIBCO non-enzymatic cell-dissociation 
solution following the company recommended 
protocol. After detachment, cells were washed twice 
in DMEM or RPMI-1641 supplemented with 0.1% 
bovine serum albumin (BSA, GIBCO), to restore 
divalent cations that are essential for the activity of 
metalloproteinases. 
Tissues 
Six snap-frozen non-small cell lung carcinoma 
(NSCLC, 4 adeno, 2 squamous cell carcinoma) 
primary tumor tissues were obtained surgically from 
stage IA-IIB lung-cancer patients under an 
IRB-approved protocol (No. REN16070229/ 
IRB9502100). Tumors were verified by 
histopathology, de-identified, stored and provided by 
the University of Pittsburgh Cancer Institute (UPCI) 
Lung Cancer (LC) SPORE Tissue Bank (TB). 
Transfection of ADAM10-/- MEFs with Human 
ADAM10 cDNA  
Two hundred thousand of ADAM10-/- MEFs per 
2 mL of antibiotic-free DMEM medium supplemented 
with 10 % FCS were seeded in a Corning 6-well plate 
(ThermoFisher Scientific) and cultured for 24 h. After 
this culture, 3 µL of Lipofectamine 2000 were mixed 
with 197 µL of serum-free/antibiotic-free DMEM 
medium and combined with 200 µL of the medium 
alone or the medium containing 1 µg of empty 
plasmid or human ADAM10-cDNA plasmid 
(OriGene), incubated at room temperature for 30 min, 
and supplemented with 600 µL of DMEM. The 
cultured ADAM10-/- MEFs were washed twice with 
DMEM and covered with 1 mL of the Lipofectamine 
and/or plasmid suspensions, and incubated for 5 h at 
37oC. The media containing Lipofectamine and/or 
plasmids were replaced with 2 mL of antibiotic-free 
DMEM medium supplemented with 10% FCS, and 
the cells were further cultured for 18 h. 
 Journal of Cancer 2017, Vol. 8 
 
http://www.jcancer.org 
3919 
 
 
Figure 1. PrAMA approach for solid tissue analysis. (A) Summary table and heat-map show 7 FRET-based polypeptide substrates with cleavage sequences (HomoPhe, 
homophenylalanine; Cha, 3-cyclohexylalanine), endogenous-protein protease substrates from which the peptides were designed, and the catalytic efficiencies with 
which various recombinant proteases cleave the substrates (for more information see ref. 35). (B) Workflow illustrates PrAMA for cell and tissue lysates. (C) 
Proof-of-principle is shown for PrAMA applied to known solutions, and one combination, of recombinant enzymes (abbreviations: rM2, recombinant MMP2; rA10, 
recombinant ADAM10; rA17, recombinant ADAM17). Normalized cleavage rates for each of the 4 solutions were measured across the 7 substrates (left), and data 
were interpreted using known enzyme-substrate preferences [as in (A)] to infer which recombinant enzymes were present in the mixture. Actual mixture 
composition (top right) and PrAMA results (bottom right) are presented. (D) Surface plots depict three-dimensional “systematic PrAMA” inference as a function of 
the two parameters sensitivity (Syntherror) and specificity (Sigmathreshold). Processing data of seven substrates obtained with recombinant MMP2, ADAM10, and 
ADAM17 were analyzed by PrAMA across varying combinations of Syntherror and Sigmathreshold parameters to reveal how these two parameters influence PrAMA 
sensitivity and specificity. The three rows of surface-plots correspond to the analyzed individual three recombinant enzyme solutions (rMMP2, rADAM10 and 
rADAM17), and the three columns of surface-plots correspond to the three individual PrAMA-inferred enzyme activities from these solutions (MMP2a, ADAM10sa 
and ADAM17sa). The color scale ranges from red to blue, which reflects the surface heights as labeled on the vertical axis. The three-dimensional surface plots shown 
in the figure depict a representation of the two-dimensional “systematic PrAMA” shown in Figs. 3C-3H. In the latter cases (Figs. 3C-H) and the rest of presented data, 
Syntherror is held constant (0.5) across a range of Sigmathreshold values. The experimental details follow those described for Fig. 1C. 
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Transfection of H441 Cells with Human 
ADAM10 and ADAM17 siRNA 
Two hundred thousand H441 cells per 2 mL of 
antibiotic-free RPMI-1640 medium supplemented 
with 10 % FCS were seeded in a Corning 6-well plate 
and cultured for 24 h. Following the culture, 6 µL of 
siRNA transfection reagent was mixed with 100 µL of 
siRNA transfection medium in tube A, and 2 µL (20 
pM) of control or human ADAM10 or human 
ADAM17 siRNA were mixed with 100 µL of siRNA 
transfection medium in tube B. The contents of tubes 
A and B were mixed, and the resulting mixture 
incubated at room temperature for 30 min. After this 
incubation, 800 µL of siRNA transfection medium 
were combined with the mixtures of siRNA 
transfection reagents and siRNA, and the resulting 
solution added to H441 cells washed with transfection 
medium. H441 cells and siRNA were co-cultured for 
24 h. The medium containing siRNA was replaced 
with antibiotic-free RPM1-1640 medium 
supplemented with 10% FCS, and transfected cells 
were continued to culture for additional 24 h. 
Stimulation of MEFs with PMA and Ionomycin 
Wild-type, ADAM10-/-, ADAM10-/- transfected 
with ADAM10 cDNA plasmid, and ADAM17-/- MEFs 
were stimulated with 1 µM PMA (phorbol 
12-myristate 13-acetate) and Ionomycin (eBioscience, 
San Diego, CA) for 2 h, before their assessment.  
Preparation of Cell and Tissue Lysates 
All procedures were performed at 0oC to 4oC. 
Single cell suspensions of viable cells were obtained 
from their cultures using the GIBCO cell dissociation 
buffer. Detached cells were washed twice in 
RPMI-1640 or DMEM medium and three times in PBS. 
Snap-frozen tissues were thawed on ice and washed 
three times in PBS. Cell and tissue lysates were 
prepared using a lysis buffer composed of 50 mM 
Tris-HCl/150 mM NaCl buffer supplemented with 
0.1% SDS, 1% sodium deoxycholate, 1% Nonidet P40, 
1% Triton X-100, and 1% EDTA-free broad-spectrum 
protease inhibitor cocktail (Roche). One million cells 
were lysed in 50 µl of the lysis buffer by 1-h 
incubation on ice and occasional vigorous vortexing. 
50 mg of tissues were lysed by homogenization in 500 
µl of the lysis buffer using the tissue grinder system 
(ThermoFisher Scientific), and subsequent 1-h 
incubation on ice and occasional vigorous vortexing 
of the homogenized tissue. The lysates were 
centrifuged at 16,000 g for 20 min, their supernatants 
were collected, protein concentrations determined 
using Quick Start Bradford Dye Reagent (Bio-Rad, 
Hercules, CA), aliquoted and stored at -80oC. 
Enzyme-linked Immunosorbent Assay  
Human ADAM10 and ADAM17 enzyme-linked 
immunosorbent assay (ELISA) kits were obtained 
from Antibodies Online Inc. (Atlanta, GA) and R&D, 
respectively. ELISAs were performed using 10 µg of 
the lysates.  
Metalloprotease Activity Assay  
The assay was performed in mixtures of 1 to 10 
µg of cell or tissue lysate proteins or 10 ng of 
recombinant enzymes, and 10 µM PEPDAB 
substrates. The assay buffer was consisted of 25 mM 
Tris-HCl buffer pH 8, supplemented with 0.1 mg/mL 
BSA, 0.0006% Brij-35, 1% glycerol, EDTA-free 
Roche-tablet and ThermoFisher Scientific-Halt 
broad-spectrum protease inhibitor cocktails in the 
concentrations indicated in Results. Halt cocktail 
contains the following inhibitors (and their targets): 
AEBSF-HCl (inhibits serine proteases), Aprotinin 
(serine proteases), Bestatin (aminopeptidases), E64 
(cysteine proteases), Leupeptin (serine/cysteine 
proteases), and Pepstatin A (aspartic acid proteases). 
To examine the inhibition of ADAM10sa in the cell 
and tissue lysates, 1 µM GI254023X [41] was 
pre-incubated with the lysates for 1 h at 21oC and 1 h 
at 37oC, before mixing the lysates and PEPDAB 
substrates. Total processing of substrates was 
obtained by their incubation with 1% trypsin. The 
enzymatic reaction was induced by the incubation of 
lysate/substrate mixtures in 96-well LUMITRAC 200 
white-wall flat-bottom immunology plates (Sigma 
Aldrich, St. Louis, Mo) at 37oC for 0.5 to 4 h. The 
fluorescence was measured in a TECAN infinite 200 
pro fluorimeter (Technical Communities, Inc., San 
Bruno, CA) using 485 nm excitation and 530 nm 
emission wavelengths. The experiments were 
performed in duplicates. The obtained data were 
computed using the following formulas: 1) 
Experimental fluorescence intensity gain (EFIG) = 
Experimental sample mean fluorescence intensity 
(ESMFI) – Background sample mean fluorescence 
intensity (BSMFI); 2) Trypsin-induced fluorescence 
intensity gain (TIFIG) = Trypsin sample mean 
fluorescence intensity (TSMFI) – BSMFI) (Suppl. Fig. 
1); 3) pM processed substrates = EFIG x 106/TIFIG. 
Data are presented as means + SD. 
Proteolytic Activity Matrix Analysis  
Proteolytic Activity Matrix Analysis (PrAMA) is 
an integrated experimental mathematical modeling 
analysis that interprets dynamic signals from panels 
of moderately specific fluorogenic polypeptide 
protease substrates (Fig. 1A) to deduce a profile of 
specific MP proteolytic activities [35]. Deconvolution 
of signals from complex mixtures of proteases is 
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accomplished by using prior data on individual MP 
cleavage signatures (Fig. 1A, matrix - C: catalytic 
specificity) for the substrate panel measured with 
purified enzymes. In essence, the method relies upon 
the assumption that the total observed substrate 
cleavage is the linear sum of cleavage from all enzyme 
activities in a complex biological mixture. As a 
consequence of this assumption, a vector of specific 
enzyme activities, E, may be inferred from a signature 
of substrate cleavages, V0, by solving the following 
equation: 
ET = [S]0-1 C-1 V0T 
where [S]0 is the concentration of substrate, and C 
comprises a matrix of kinetic parameters that describe 
the efficiency (kcat/KM) with which particular 
enzymes cleave the substrates [34] (Figs. 1B, 1C). 
PrAMA is performed with adjustment of two 
parameters, “Syntherror” and “Sigmathreshold” 
which defines synthetic errors and statistical 
significant thresholds, respectively, which are used to 
obtain accuracy. These two parameters effectively 
control assay sensitivity and specificity, respectively 
[35]. The analysis was performed using combinations 
of 10 to 40 various systematically graded Syntherror 
and Sigmathreshold parameters (the lowest 0.05 to 
0.1, the highest 1.0 to 2.0). The analysis, named 
“systematic PrAMA”, searched for 100% sensitivity 
and 100% specificity combinations of Syntherror/ 
Sigmathreshold parameters, which showed no 
cross-reactivity of recombinant ADAM10 and/or 
ADAM17 (Fig. 1D), wild-type and gene knockout 
cells, gene knockout and gene restored cells, and 
control and gene silenced cells. The three-dimensional 
PrAMA surface plots depict a landscape of how the 
two parameters sensitivity and specificity (Syntherror 
and Sigmathreshold) influence the inference results 
(Fig. 1D). To simplify PrAMA interpretation, 
especially when comparing across multiple 
experiments, subsequent PrAMA results used a fixed 
high-sensitivity Syntherror parameter (typically, 0.5) 
that was determined based on Fig. 1D and previous 
optimization [35] data, and systematically graded 
Sigmathreshold parameters to maximize both 
sensitivity and specificity. This procedure thus 
yielded a two-dimensional “systematic PrAMA” 
showing how robust protease activity inference was 
to the significance threshold parameter, 
Sigmathreshold. Ten thousand bootstrapping 
repetitions were typically performed for each dataset 
analyzed with standard errors across bootstrapping 
replicates. The computation was performed using 
Matlab 2009a MathWorks (Natick, MA).  
Flow Cytometry of Cell Surface Enzymes  
Suspensions of viable cells were obtained from 
adherent-cell cultures using the GIBCO cell 
dissociation buffer. Detached cells were washed twice 
with PBS supplemented with 0.1% FCS and 0.01% 
Azide, and stained with fluorochrome-conjugated 
isotype-control, anti-human ADAM10 and ADAM17 
extracellular-domain, or anti-mouse ADAM10 
extracellular-domain mAbs. The stained cells were 
analyzed by single-color flow cytometry using the 
Accuri C6 cytometer (BD Biosciences, San Jose, CA, 
CA) and FlowJo v 10 (FlowJo, LLC Ashland, OR) 
software. 
Statistics 
 Data were statistically evaluated using the SPSS 
(version 10.0 SPSS Inc., Chicago, IL) program 
package. Data are reported as means + SD or SE. 
Statistical significance of data was assessed using the 
Student’s t test. p values <0.05 were considered 
significant. 
Results  
PrAMA measures Specific Sheddase Activities 
of Recombinant ADAM10 and ADAM17 in the 
Presence of non-MP Protease Inhibitors 
To efficiently measure ADAM10 and ADAM17 
activities, PEPDAB005, 010, 014, 013 and 022 FRET 
substrates were chosen based on their known ability 
to be efficiently cleaved with relative selectivity by 
ADAM sheddases. Two additional substrates, 
PEPDAB008 and 011, which exhibit greater preference 
for MMPs, were also used to account for non-ADAM 
sheddase metalloproteinase activity [35-38] (Fig. 1A). 
Although the FRET substrates PEPDAB005 and 010 
contain the TNF cleavage sites, and PEPDAB014 and 
022 have the TGFα and CD23 cleavage sites, 
respectively, they are not only variably susceptible to 
ADAM17 and ADAM10, but also to ADAM8, 
ADAM9, ADAM12, and to a variety of other MPs 
[35-38] (Suppl. Fig. 2, Fig. 1A). Based on the 
characteristic differential processing patterns of the 
moderately specific substrates with the recombinant 
MPs, PrAMA was modeled to more selectively 
measure individual enzyme activities in a limited 
complexity mixtures of natural MPs that are 
expressed on the cell surface of live cells [35]. Fig. 1B 
shows the PrAMA workflow described here. As a 
validating proof-of-principle, PrAMA is able to 
correctly identify individual recombinant enzymes 
and a mixture thereof based on their observed 
cleavage patterns across the 7 substrates used in this 
work (Figs. 1C, 1D). While such recombinant enzyme 
experiments and many more described previously 
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[35] are encouraging, measurements of specific 
enzyme activities in whole tissue presents additional 
challenges. 
To specifically measure ADAM10sa and 
ADAM17sa in tissue lysates containing not only the 
cell-surface but also a plethora of cytoplasmic and 
nuclear “promiscuous” proteases, it might be 
necessary to selectively inhibit the non-MP proteases 
without affecting the enzymes of interest. We 
examined whether the cocktails of broad-spectrum 
non-MP protease inhibitors 
Roche tablet (Roche) and 
ThermoFisher Scientific Halt 
(Halt) affect enzyme 
activities of human NSCLC- 
H441 cell lysates and 
rADAM10 and rADAM17 
(Fig. 2). Both cocktail 
inhibitors strongly inhibited 
in a dose-dependent manner 
(p=0.002 to p<0.0001) the 
cell-lysate processing of the 
prototypic ADAM10/ 
ADAM17 substrate PEPDA-
B005, though Halt did so 
more effectively (p=0.012 to 
p=0.0012) (Figs. 2A, 2B). The 
company-recommended 
Roche and Halt concentra-
tions of 0.5% to 1% decreased 
substrate processing in the 
cell lysate by 50% to 60% and 
69% to 82%, respectively. The 
remaining cell-lysate enzyme 
activity after this inhibition 
should be mediated mostly 
by unaffected MPs, including 
ADAM10 and ADAM17. To 
confirm this possibility, we 
tested whether the protease 
inhibitors affect rADAM10 
and rADAM17 processing of 
PEPDAB005 in a Tris-based 
assay buffer (Figs. 2C-2F). At 
0.5% and 1% concentrations, 
Roche and Halt inhibitors 
induced low, nonsignificant 
suppression (5-20%, p>0.07) 
of rADAM10 (Figs. 2C, 2D) 
and rADAM17 (Figs. 2E, 2F) 
activities, but they suppress-
ed 30% to 50% of the enzyme 
activities, when administered 
at 2% to 3% concentrations 
(rADAM10: p=0.048 to 
p=0.019; rADAM17: p=0.05 
to p=0.0038). Again, Halt 
appeared to be more potent 
than Roche, especially 
against rADAM17 (p=0.026 
 
 
Figure 2. Broad-spectrum Roche and Halt non-MP protease inhibitors decrease large proportions of cell-lysate 
enzyme activities, but do not affect rADAM10 and rADAM17 sheddases activities. Tris-based reaction buffer 
solutions (150 µL) of 10 µM PEPDAB005, 2 µg of H441-cell lysate (A, B), 10 ng of rADAM10 (C, D), 10 ng of 
rADAM17 (E, F) and indicated concentrations of Roche and Halt inhibitors were distributed into wells of 96-well 
LUMITRAC-200 plates. Additionally, the effects of different concentrations of DMSO on rADAM10 and rADAM17 
processing of PEPDAB005 were tested (G, H). Negative-control wells contained the assay buffer supplemented only 
with 10 µM of PEPDAB005, and positive-control (total substrate processing) wells contained the assay buffer 
supplemented with 1 µM of PEPDAB005 and 1% trypsin. Plates were incubated at 37oC for 4h. The fluorescence was 
measured with a TECAN infinite 200 pro fluorimeter, using an excitation wavelength of 485 nm and an emission 
wavelength of 530 nm. The presented data are pM means of duplicate measurements + SD (A, C, E, G) and % 
inhibition (B, D, F, H) of PEPDAB005 processing at 3 h of incubation. (A, B) Roche and Halt inhibitors significantly 
inhibited in a dose-dependent manner H441-cell lysate-mediated processing of PEPDAB005 (p=0.002-0.0001). Halt 
was more effective (p=0.012 to p=0.0012). Processing of PEPDAB005 by rADAM10 (C, D) and rADAM17 (E, F) was 
slightly (non-significantly) inhibited with 0.25%, 0.5 or 1%, but significantly inhibited with 2% and especially 3% of the 
protease inhibitors (rADAM10: p=0.048 to p=0.019; rADAM17: p=0.05 to p=0.0038). Halt cocktail did so more 
efficiently than the Roche cocktail (p=0.026 to p=0.013). (G, H) DMSO did not inhibit rADAM10 or rADAM17 
enzyme activity.  
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to p=0.013). The solvent of Halt inhibitors, DMSO, 
had no effect on the enzyme activities in any of the 
tested concentrations (Figs. 2G, 2H), indicating that 
the significant suppressive effects of higher 
concentrations of the protease inhibitors were caused 
by the inhibitors themselves, and not by the vehicle. 
Combining the two non-MP protease-inhibitor 
cocktails could target a broader spectrum of and have 
a greater inhibiting efficiency on non-MP proteases. 
Consequently, this strategy could increase the 
specificity of PrAMA analyses of ADAM10sa and 
ADAM17sa in cell and tissue lysates. However, the 
combined use of inhibitors could also have an adverse 
effect on ADAM10sa and ADAM17sa. The combined 
Roche/Halt cocktails at a concentration of 0.5% only 
slightly, non-significantly, suppressed processing of 
PEPDAB005 by rADAM10 
(10%) and rADAM17 
(15%), and did not affect 
processing of PEPDAB010, 
PEPDAB08, PEPDAB013 or 
PEPDAB014 (Figs. 3A, 3B). 
In contrast, the combined 
inhibitors at a concentr-
ation of 1% significantly 
suppressed processing of 
PEPDAB005 with rADAM-
10 (43%, p=0.0049) and 
rADAM17 (40%, p=0.0046), 
and increased processing of 
PEPDAB010 with rADAM-
17 (23%, p=0.0038), but had 
no effect on the processing 
of the other tested 
substrates with either 
enzyme. These findings 
indicate that higher 
concentrations of protease 
inhibitors could modify the 
susceptibility of PEPDAB-
005 and PEPDAB010 to 
processing with, but not 
activity of rADAM10 or 
rADAM17.  
Next, we tested 
whether the observed 
changes of the substrate 
processing in the presence 
of combined Roche/Halt 
protease inhibitors could 
affect PrAMA (Figs. 
3C-3H). The data presented 
in Figs. 3A-3B were 
analyzed using the PrAMA 
fixed sensitivity parameter 
Syntherror (0.5) and the 
systematically increased 
specificity parameter Sigm-
athreshold from 0.0 to 2.0, 
to maximize the assay 
specificity. PrAMA of 
rADAM10 measured true- 
positive ADAM10sa with-
 
 
Figure 3. Combined solutions of 0.5% Roche and 0.5% Halt inhibitors do not affect recombinant ADAM10-mediated 
processing of PEPDAB substrates or PrAMA-ADAM10 sheddase activity. Processing of 5 substrates with rADAM10 (A) 
and rADAM17 (B) in the absence and presence of 0.5% or 1% combined inhibitors is presented. Data are pM means of 
duplicate measurements + SD of processed substrates. The decreases of PEPDAB005 processing with rADAM10 and 
rADAM17 and the increases of PEPDAB010 processing with rADAM17 in the presence of 1% Roche/Halt inhibitors are 
significant (p=0.0049, p=0.0046 and p=0.0038, respectively). PrAMA-ADAM10sa data of rADAM10 processing of 
PEPDAB substrates in the absence (C) and presence of 0.5% (D) or 1% (E) combined inhibitors are presented. 
PrAMA-ADAM17sa data of rADAM17-processing of substrates in the absence (F) and presence of 0.5% (G) or 1% (H) 
combined inhibitors are presented. The experiments in (A) and (B) were performed using similar conditions to those 
presented in Fig. 1. PrAMA was performed using a fixed 0.5 Syntherror parameter and systematically increased 
Sigmathreshold parameters from 0.0 to 2.0. Data are PrAMA ADAM10sa (C, D, E) and PrAMA ADAM17sa (F, G, H) 
arbitrary units (AU). PrAMA standard errors were <5%.The arrow-had line in (D) indicates that the PrAMA specificity 
Sigmathreshold parameters > 1.0 detects only true-positive rADAM10-ADAM10sa without any false-positive 
ADAM17sa. 
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out false-positive ADAM17sa using Syntherror/ 
Sigmathreshold 0.5/1.2-2.0 (Fig. 3C), and 0.5/1.0-2.0 
(Fig. 3D) or 0.5/0.8-2.0 (Fig. 3E) scripts in the absence 
(0%) and presence of 0.5% or 1% inhibitors, 
respectively. Importantly, the separation of rADAM10 
true-positive ADAM10sa and false-positive 
ADAM17sa was better with protease inhibitors, and 
the sensitivity of ADAM10sa PrAMA was unaffected 
in the presence of 0.5% inhibitors. In contrast, the 
sensitivity of ADAM10sa PrAMA was significantly 
decreased in the presence of 1% inhibitors. On the 
other hand, PrAMA of rADAM17 showed high 
true-positive ADAM17sa completely separated from 
undetectable false-positive ADAM10sa using the 
Syntherror/Sigmathreshold 0.5/0.0-1.8 scripts, 
regardless of whether the inhibitors were present or 
absent in the assay buffer. However, the sensitivity of 
PrAMA ADAM10sa appeared to be more than 
two-log units higher than that of the PrAMA 
ADAM17sa. These data show that Tris-based assay 
buffer supplemented with 0.5% combined 
Roche/Halt protease-inhibitor cocktails strongly 
suppress non-MP proteases without affecting 
recombinant or natural ADAM10sa and ADAM17sa. 
They also show that the high specificity PrAMA 
Syntherror/Sigmathreshold 0.5/>1.0 scripts measure 
only the true-positive and distinguish accurately 
recombinant ADAM10sa and ADAM17sa, indicating 
that these PrAMA scripts might be optimal for the 
examination of the natural ADAM10sa and 
ADAM17sa in cell and tissue lysates. Validation of the 
modified PrAMA for examination of natural 
ADAM10sa and ADAM17sa in cell and tissue lysates 
was further performed as described below.  
Modified PrAMA detects ADAM10sa and 
ADAM17sa Presence in Wild-type Cells and 
Absence in Gene-knockout Cells 
PrAMA has demonstrated the ability to detect 
ADAM10sa and ADAM17sa presence and absence on 
the surface of live wild-type and ADAM10-/- and 
ADAM17-/- MEFs, respectively [35]. We examined 
whether the modified PrAMA could similarly 
measure the endogenous enzyme activities in lysates 
of these cells (Fig. 4). ADAM10+/-, ADAM10-/-, 
ADAM17+/+ and ADAM17-/- MEFs were stimulated 
with PMA/Ionomycin, lysed and their lysates 
examined for enzyme activities in the presence of 
non-MP inhibitors (0.5% Roche/Halt) using 7 
PEPDAB substrates, to increase PrAMA specificity 
[35] (Suppl. Fig. 3). The wild-type MEF lysates 
showed significantly higher enzyme activities than 
the corresponding knockout MEF lysates against 
PEPDAB005, 010, 011, 014 and 022 substrates (Figs. 
4A, 4B; ADAM10+/- vs ADAM10-/- MEFs ADAM17+/+ vs 
ADAM17-/- MEFs: p<0.0001 and p<0.001, p=0.0056 
and p<0.001, p=0.0016 and p=0.0025, p=0.0016 and 
p=0.009, and p=0.006 and p=0.004, respectively). 
However, the ADAM10-/- MEF lysate processed less 
PEPDAB005, 014 and 022, and more PEPDAB010 than 
the ADAM17-/- MEFs lysate. PrAMA detected 
relatively high levels of true-positive ADAM10sa in 
ADAM10+/- MEF lysates and relatively low levels of 
false-positive ADAM10sa in both ADAM10+/- and 
ADAM10-/- MEF lysates (Figs. 4C, 4E). Increases of 
PrAMA specificity by systematically increasing 
Syntherror/Sigmathreshold scripts from 0.5/0.0 to 
0.5/1.7 led to gradual decreases of both true-positive 
and false-positive ADAM10sa, and increases of the 
proportion of true-positive ADAM10sa from 57% to 
100%, respectively. Importantly, the PrAMA scripts 
between 0.5/1.7 and 0.5/1.9 detected only 
true-positive ADAM10sa in wild-type MEF without 
any false-positive ADAM10sa in knockout MEF. To 
detect ADAM17sa in MEF, we had to use lower 
specificity PrAMA (Syntherror/Sigmathreshold 
<0.5/0.95). The lower specificity PrAMA detected 
relatively low levels of true-positive ADAM17sa in 
ADAM17+/+ MEF lysate and significant levels of 
false-positive ADAM17sa in both ADAM17+/+ and 
ADAM17-/- MEF lysates (Figs. 4D, 4F). However, the 
systematic increases of PrAMA specificity by 
increasing Syntherror/Sigmathreshold scripts from 
0.5/0.0 to 0.5/0.85 led to decreases of both 
true-positive and false-positive ADAM17sa, and 
increases of the proportion of true-positive 
ADAM17sa from 31% to 100%, respectively. This 
time, the absolute (100%) specificity was obtained 
using the PrAMA 0.5/0.8 script. These data show that 
the modified PrAMA can detect and measure with 
significant accuracy ADAM10sa and ADAM17sa in 
wild-type MEFs, and their absence in the gene 
knockout MEFs. They also show that wild type MEFs 
contain different amounts of ADAM10sa and 
ADAM17sa and, therefore, different PrAMA 
specificities has to be applied to specifically measure 
them.  
Modified PrAMA detects Restoration of 
ADAM10 in ADAM10-/- MEFs  
To confirm and extend the above findings, we 
investigated whether the modified PrAMA could 
detect newly produced ADAM10sa in ADAM10-/- 
MEFs following the enzyme-gene restoration. 
ADAM10-/- MEFs were treated either with 
Lipofectamine alone or Lipofectamine/ human 
ADAM10-cDNA containing plasmid, incubated for 24 
h, and activated with PMA/Ionomycin. Controls also 
included untreated and Lipofectamine/empty 
plasmid transfected cells (data not shown). These cells 
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were examined by flow cytometry for the surface 
expression of human ADAM10 protein, and their 
lysates were tested by the modified PrAMA for the 
presence of ADAM10sa (Fig. 5). ADAM10-cDNA 
transfected ADAM10-/- MEFs showed the expression 
of human ADAM10 protein on the cell surface (Fig. 
5A), and their lysates contained significantly 
increased enzyme activities relative to the lysates of 
Lipofectamine alone treated cells (Fig. 5B; 
PEPDAB010: p=0.002; PEPDAB005, 011, 014 and 022: 
p<0.001 to p<0.0001). Consequently, PrAMA detected 
relatively high levels of true-positive ADAM10sa in 
the lysate of ADAM10-cDNA transfected ADAM10-/- 
MEFs, and low levels of false-positive ADAM10sa in 
the lysates of both Lipofectamine alone treated and 
ADAM10-cDNA transfected ADAM10-/- MEFs (Figs. 
5C, 5D). Systematic increases of PrAMA specificity 
(Syntherror/Sigmathreshold scripts from 0.5/0.0 to 
0.5/1.5) led to gradual decreases of both true-positive 
and false-positive ADAM10sa, and increases of the 
proportion of true-positive ADAM10sa in 
ADAM10-cDNA transfected cells from 58% to 100%, 
respectively. The highest (100%) specificity 
ADAM10sa was also obtained with the PrAMA script 
0.5/1.6. These findings show that the modified 
PrAMA can accurately detect and measure newly 
produced ADAM10sa in 
ADAM10-/- MEF following 
transfection of human 
ADAM10 gene.  
Modified PrAMA 
detects in Human 
Cancer Cells 
ADAM10sa and 
ADAM17sa Decreases 
after Gene Silencing  
Next, we examined 
whether the modified 
PrAMA could specifically 
measure down-modula-
tion of ADAM10sa and 
ADAM17sa in the lysates 
of the prototypic human 
NSCLC cells H441 transf-
ected with ADAM10 and 
ADAM17 siRNA, respect-
ively (Fig. 6). Untreated 
H441 cells showed a 
26-fold higher levels of 
cell-surface ADAM10 
(Fig. 6A, Suppl. Fig. 4A) 
than ADAM17 protein 
(Fig. 6B, Suppl. Fig. 4B), 
as determined by flow 
cytometry, but 5-fold 
lower levels of ADAM10 
than ADAM17 protein in 
the cell lysate, as 
measured by ELISA 
(Suppl. Figs. 4C). The 
H441 cell lysate mediated 
significant and charact-
eristic processing of 
PEPDAB substrates (Fig. 
6C), and exhibited 
presence of significant 
amounts of ADAM10sa 
 
 
Figure 4. Modified PrAMA detects ADAM10sa and ADAM17sa presence in wild-type and absence in ADAM10-/- and 
ADAM17-/- MEF lysates, respectively. ADAM10+/-, ADAM10-/- (A, C, E), ADAM17+/+ and ADAM17-/- (B, D, F) MEFs were 
activated with PMA/Ionomycin and lysed. The 150 µL Tris solutions of 2 µg cell lysates, 10 µM PEPDAB substrates and 
0.5% Roche/Halt protease inhibitors were incubated for 4 h at 37oC, and the developed fluorescence was recorded hourly 
using TECAN fluorimeter. The presented experiments are representative of 5 performed. The enzymatic activity data are 
shown as pM means of duplicate measurements + SD of the processed substrates (A, B). The decreased processing of 
PEPDAB005, 010, 011, 014 and 022 with knockout MEF lysates is significant (ADAM10+/- vs ADAM10-/- MEFs and ADAM17+/+ 
vs ADAM17-/- MEFs: p<0.0001 and p<0.001, p=0.0056 and p<0.001, p=0.0016 and p=0.0025, p=0.0016 and p=0.009, and 
p=0.006 and p=0.004, respectively). Systematic PrAMA data using Syntherror/Sigmathreshold parameters 0.5/0.0 to 
0.5/2.0 and 0.5/0.0 to 0.5/1.0 are presented as ADAM10sa AU (C) and ADAM17sa AU (D), respectively. Standard errors 
of PrAMA data were 2.5% to 5.8%. True-positive ADAM10sa and ADAM17sa in ADAM10+/- and ADAM17+/+MEFs, 
respectively, are presented as % of specific enzyme activities in wild-type MEFs, containing both the true-positive and 
false-positive activities, relative to ADAM10-/- (E) and ADAM17-/- (F) ME Fs containing only the false-positive activities, 
respectively. 
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(Fig. 6D) and ADAM17sa (Fig. 6E). Proportional 
equations of rADAM10-ADAM10sa and 
rADAM17-ADAM17sa with the cell-lysate 
ADAM10sa and ADAM17sa, respectively, indicated 
that H441-cell lysate contained more ADAM10sa than 
ADAM17sa, which correlated better with the 
cell-surface expression than with the cell-lysate 
quantities of the enzyme proteins.  
Silencing ADAM10 or ADAM17 in H441 cells 
with ADAM10 and ADAM17 siRNA led to 70% to 
95% and 35% to 70% decreases of ADAM10 and 
ADAM17 protein expression on the cell surface, 
respectively (Figs. 6A, 6B; Suppl. Figs. 4A, 4B). 
Subsequently, processing of PEPDAB substrates was 
variably decreased (Fig. 6C; ADAM10 siRNA: 
PEPDAB005, p=0.0023; PEPDAB010, p=0.012; 
PEPDAB011, p=0.048; PEPDAB014, p=0.07. ADAM17 
siRNA: PEPDAB005, p=0.0077; PEPDAB010, p=0.017; 
PEPDAB011, p=0.06; PEPDAB014, p=0.0.019). 
Consequently, ADAM10sa (Figs. 6D, 6F) and 
ADAM17sa (Figs. 6E, 6G) were reduced in the cell 
lysates from 67% (Syntherror/Sigmathreshold 0.5/1.0 
script) to 88% (0.5/1.5 script) and from 28% (0.5/1.0 
script) to 42% (0.5/1.4 script), respectively. These 
changes of ADAM10sa and ADAM17sa correlated 
with those of the cell-surface levels of ADAM10 and 
ADAM17 proteins. In addition, the high similarity of 
the false-positive ADAM10sa in MEFs and the 
remaining ADAM10sa in H441 cells after the effective 
gene silencing indicated that the false-positive 
ADAM10sa was low in H441 cells, and that the 
high-specificity PrAMA (i.e., Syntherror/ 
Sigmathreshold >0.5/1.4) mostly measured in these 
cancer cells the true-positive enzyme activities. 
Therefore, the modified PrAMA can accurately 
measure ADAM10sa and ADAM17sa in human 
cancer cells. 
 
 
Figure 5. Modified PrAMA detects ADAM10sa in ADAM10-/- MEFs following restoration of ADAM10 gene. ADAM10-/- MEFs were transfected with 
Lipofectamine/human ADAM10-cDNA or treated with Lipofectamine alone and incubated for 24 h. In some experiments, empty plasmid-transfected ADAM10-/- MEFs 
were used as an additional control. (A) ADAM10-/- MEFs transfected with human ADAM10-cDNA express human ADAM10 on cell surface. Lipofectamine treated 
(empty histogram) and Lipofectamine/human ADAM10-cDNA transfected (filled histogram) cells were stained with PE-conjugated anti-human ADAM10 and examined 
by flow cytometry. Cells were also stained with PE-conjugated anti-mouse ADAM10 or isotype-control mAbs, and their mean fluorescence intensities (MFIs) were 
similar to that of the cells treated with Lipofectamine alone and stained with PE-conjugated anti-human ADAM10 mAb (data not shown). Data are from one of two 
similar experiments performed. (B) Lysates of ADAM10-/- MEFs transfected with human ADAM10-cDNA contain increased enzyme activities as assessed with all 7 
PEPDAB substrates. Lipofectamine alone treated and Lipofectamine/human ADAM10-cDNA transfected ADAM10-/- MEFs were lysed. The 150 µL Tris solutions 
containing 2 µg cell lysates, 10 µM PEPDAB substrates and 0.5% Roche/Halt inhibitors were incubated for 4 h at 37oC, and the developing fluorescence was recorded 
every hour. Data are representative of three experiments performed. They are pM means of duplicate measurements + SD of processed substrates. The increases 
of PEPDAB processing with the lysates of ADAM10-cDNA transfected cells are significant (PEPDAB010: p= 0.002; PEPDAB005, 008, 011, 013, 014 and 022: p<0.001 
to p<0.0001). (C) PrAMA-ADAM10sa AU was obtained by analyzing the enzyme activity data at 4 h of incubation using the systematically increased 
Syntherror/Sigmathreshold parameters from 0.5/0.0 to 0.5/2.0. Standard errors of PrAMA data were 1.3% to 2.6%. (D) True-positive ADAM10sa restoration in 
ADAM10-/- MEFs is presented as % of the specific enzyme activity in ADAM10-cDNA transfected MEFs, containing both the true-positive and false-positive activities, 
relative to Lipofectamine-alone treated ADAM10-/- MEFs, containing only the false-positive activity. 
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Figure 6. Modified PrAMA detects decreases of ADAM10sa and ADAM17sa in human cancer cells after silencing of the corresponding enzyme genes. H441 cells 
were transfected with human ADAM10 siRNA, ADAM17 siRNA or scrambled siRNA or were treated with transfection reagents alone for 48 h. In some 
experiments, control cells were also untreated. (A, B) Cells were stained with PE-conjugated IgG control mAb, anti-human ADAM10 (A) or anti-human ADAM17 
mAb (B) and analyzed by flow cytometry. Empty histograms represent MFI of H441 cells stained with isotype control mAb. Dark gray histograms represent MFI of 
H441 cells treated with scrambled siRNA and stained with PE-conjugated anti-ADAM10 (A) or anti-ADAM17 (B) mAbs. Light grey histograms represent MFI of H441 
cells treated with ADAM10 (A) or ADAM17 (B) siRNA and stained with PE-conjugated anti-ADAM10 or anti-ADAM17 mAbs, respectively. Data are from a 
representative experiment of 8 similar performed (Suppl. Figs. 4A, 4B). In the presented experiment, ADAM10 and ADAM17 siRNA induced 90% and 45% 
decreases of ADAM10 and ADAM17 protein expression on H441 cell surface, respectively. (C) After performing transfection, 2 µg of cell lysates were tested for 
processing PEPDABs in the presence of 0.5% Roche/Halt protease inhibitors. Data are from one of seven similar experiments performed. They are pM means of 
duplicate measurements + SD of processed substrates. Processing of PEPDAB substrates was differently decreased in H441 cells transfected with ADAM10 or 
ADAM17 siRNA (PEPDAB005: p=0.0023 and p=0.0077; PEPDAB010: p=0.012 and p=0.017; PEPDAB011: p=0.048 and p=0.06; and PEPDAB014: p=0.07 and 
p=0.0.019, respectively). The substrate processing data obtained at 4 h of incubation were analyzed using the systematically increased Syntherror/Sigmathreshold 
parameters from 0.5/0.0 to 0.5/2.0. The resulted PrAMA ADAM10sa (D) and ADAM17sa (E) AU are shown. PrAMA standard errors were 1.3% to 8.9%. Decreases 
of ADAM10sa and ADAM17sa in ADAM10 (F) and ADAM17 (G) siRNA transfected H441 cells, respectively, are presented as % of the specific enzyme activities in 
the siRNA transfected cells relative to transfection reagent-treated cells. Proportion-equation analysis of PrAMA-ADAM10sa and PrAMA-ADAM17sa of rADAM10 
and rADAM17 vs the scrambled siRNA-transfected H441-cell lysates, respectively, showed that 10 µg of H441-cell lysate contained 17.0 ng of ADAM10sa and 1.65 
ng of ADAM17sa. 
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 Modified PrAMA detects GI254023X-induced 
Inhibition of ADAM10sa in Human 
Cancer-Cell and Tumor-tissue Lysates  
Finally, we tested whether the modified PrAMA 
could measure the GI254023X-induced suppression of 
ADAM10sa [41] in human cancer-cell and 
tumor-tissue lysates (Fig. 7). NSCLC H441-cell and 
NSCLC T2495-tumor-tissue lysates were diluted with 
Tris-based reaction buffer supplemented with 0.5% 
Roche/Halt protease inhibitors and either vehicle 
(Control) or 1 µM G1254023X, and examined for the 
processing of PEPDAB substrates and presence of 
ADAM10sa and ADAM17sa. GI254023X significantly 
inhibited the lysate-mediated processing of 
PEPDAB005, 010 and 022 (H441: p=0.017, 0.0041 and 
0.0058; T2495: p=0.05, 0.040, 0.08, respectively), and 
the inhibition of PEPDAB005 processing was more 
pronounced in T2495-tissue lysate than H441-cell 
lysate (Figs. 7A, 7B). The high specificity PrAMA 
(Syntherror/Sigmathreshold 0.5/1.2 and 0.5/1.4 
scripts) detected 37% and 42% decreases of 
ADAM10sa in GI254023X supplemented H441-cell 
(Figs. 7C, 7E) and T2495-tumor lysates (Figs. 7D, 7F), 
respectively. These findings confirm the gene 
silencing data, and indicate that modified PrAMA can 
accurately measure the ADAM activities not only in 
cells but also in solid tissues.  
Modified PrAMA 
simultaneously 
measures 
ADAM10sa and 
ADAM17sa in 
Multiple Specimens 
of Human Tumors 
The presented 
data show that the 
modified PrAMA can 
measure with signific-
ant sensitivity, specif-
icity and accuracy not 
only the recombinant 
human but also the 
natural (endogenous) 
mouse and human 
ADAM10sa and 
ADAM17sa in mouse 
and human cell 
lysates. They also 
indicate that this test 
could specifically 
measure the enzyme 
activities in tumor 
lysates. To confirm 
these findings and test 
the potential clinical 
applicability of the 
enzyme-activity assay, 
we simultaneously 
examined ADAMA10 
and ADAM17 protein 
levels and specific 
sheddase activities in 
five human tumor 
tissues obtained from 
NSCLC patients (Fig. 
8). We found that all 
the lysates contained 
 
 
Figure 7. Modified PrAMA detects decreases of ADAM10sa in human-cell and -tissue lysates exposed to ADAM10 inhibitor. 
H441-cell (A) and T2495-tissue (B) lysates (2 µg) were supplemented with 0.5% Roche/Halt protease inhibitors, vehicle 
(Control) or GI254023X (1 µM), and PEPDAB substrates (10 µM), and incubated for 4 h. The developing fluorescence was 
measured hourly. The presented data are pM means of duplicate measurements + SD of processed substrates, and are 
representative of ten experiments performed. The GI254023X-mediated inhibitions of PEPDAB005, 010 and/or 022 processing 
with the lysates are significant (H441: p=0.017, 0.0041 and 0.0058; T2495: p=0.05, 0.04 and 0.08, respectively). The substrate 
processing data were analyzed using the systematically increased Syntherror/Sigmathreshold parameters from 0.5/0.0 to 0.5/2.0. 
The obtained data at 4 h incubation are presented as PrAMA ADAM10sa AU of H441-cell (C) and T2495-tissue (D) lysates. 
PrAMA standard errors were 1.2% to 9%. Decreases of ADAM10sa in H441-cell (E) and T2495-tissue (F) lysates are presented 
as % of the specific enzyme activities in the control lysates relative to the GI254023X treated lysates. 
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significant, but various quantities of ADAM10 and 
ADAM17 proteins, having approximately 13-fold 
more ADAM17 than ADAM10, as measured by 
ELISA (Fig. 8A). 
 Mimicking a small-scale clinical laboratory 
testing, we simultaneously examined in duplicates the 
enzyme activities of the five tumor lysates using 7 
PEPDAB substrates. The preparation of dilutions of 
lysates and substrates and their loading into 96-well 
assay-plate took 0.5 h. The incubations and 
measurements of the fluorescence required 4 h. The 
data analysis required additional 3 h. The obtained 
enzyme-activity duplicate data were robust and with 
less than 5% standard deviation. The resulted PrAMA 
ADAM10sa and ADAM17sa data were also robust 
and similar to those obtained with the lysates of H441 
cells and T2495 tumor tissue (Figs. 7, 8), indicating 
their consistency. We found that the five tumor-tissue 
lysates characteristically processed substrates, 
showing a high efficiency against PEPDAB005, 008 
and 010, a moderate efficiency against PEPDAB014 
and 022, and a low efficiency against PEPDAB011 and 
013. However, the levels of enzyme activities of the 
lysate specimens notably varied, as supported by the 
large standard deviations of their means (Fig. 8B). 
Consistent with the substrate processing data, the 
high specificity PrA-
MA (Syntherror/Sigm-
athreshold scripts >0.5 
/1.4) measured relati-
vely large, but various 
amounts of ADAM10-
sa in the tumor lysates 
(Figs. 8C, 8E). On the 
other hand, the high 
specificity PrAMA 
could not detect any 
ADAM17sa in these 
tumor lysates (Fig. 
8D). However, the 
lower specificity PrA-
MA (Syntherror/Sigm-
athreshold <0.5/0.5 
scripts) also measured 
significant, but various 
amounts of ADAM17-
sa (Figs. 8D, 8F), which 
inversely correlated 
with those of 
ADAM10sa in the 
same tumor lysates. 
These findings indicate 
that ADAM10sa was 
more abundant than 
ADAM17sa in these 
tumor tissues. In 
addition, the amounts 
of the enzyme proteins 
and sheddase activities 
inversely correlated, 
indicating that high 
levels of inactive and 
low levels of active 
ADAM10 and ADAM-
17 were present in 
NSCLC tumor lysates. 
Taking together, the 
modified PrAMA, 
 
 
Figure 8. Modified PrAMA efficiently measures ADAM10sa and ADAM17sa in multiple human tumor-tissue specimens. (A) 
NSCLC tumor lysates contain less ADAM10 than ADAM17 protein. ADAM10 and ADAM17 were quantified in lysates of 5 
human NSCLC tumor tissues using ELISAs. Presented data are means pg/10 µg lysates of ADAM10 and ADAM17 proteins + 
SD of 5 tumor tissues. (B) NSCLC tissue lysates process high amounts of PEPDAB05, 008 and 010, moderate amounts of 
PEPDAB014 and 022, and low amounts of PEPDAB011 and 013. Duplicates of 150 µL of Tris-based reaction buffer 
supplemented with NSCLC tumor-tissue lysates (10 µg/replicate), 0.5% Roche/Halt protease inhibitors and 10 µM of PEPDABs 
were incubated at 37oC, and fluorescence quantified hourly for 4 h. Data are pM means of duplicate measurements + SD of 
processed substrates with the 5 tissue lysates. (C, E) PrAMA ADAM10sa and (D, F) PrAMA ADAM17sa are robust but 
quantitatively different. The 4 h substrate processing data were analyzed using the systematically increased 
Syntherror/Sigmathreshold scripts from 0.5/0.0 to 0.5/2.0. Presented data are of the individual tissue lysates. PrAMA standard 
errors were 2.7% to 5.4%. Proportion-equation analysis of rADAM10 and rADAM17, and the tissue lysate PrAMA-ADAM10sa 
and PrAMA-ADAM17sa, respectively, showed that 10 µg of these tissue lysates contained 20.0 ng of ADAM10sa and 1.25 ng 
of ADAM17sa. 
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alike a standard high through-put clinical-laboratory 
test, can examine simultaneously and with significant 
sensitivity, specificity and accuracy ADAM10sa and 
ADAM17sa in multiple tumor-tissue specimens.  
Discussion 
Clinically applicable tests that could measure 
specific enzyme activities are unavailable [1]. PrAMA 
has been recently developed as a high throughput 
real-time assay to specifically measure the individual 
activities of relatively small variety of 
plasma-membrane integral MPs of live cells [35]. 
Herein, we introduce a clinically applicable 
modification of PrAMA to specifically measure 
ADAM10sa and ADAM17sa in cells and solid tissues. 
The modification includes selective measurements of 
MP activities in cell and tissue lysates supplemented 
with non-MP protease inhibitors, and maximization 
of ADAM10sa and ADAM17sa specificity by 
performing PrAMA while systematically changing 
the specificity Sigmathreshold parameter.  
The optimal concentration of Roche/Halt 
non-MP protease inhibitors of 0.5% suppressed 60% 
to 80% of enzyme activities in cell and tissue lysates 
without affecting recombinant or natural ADAM10sa 
and ADAM17sa. Thus, the selective inhibition of 
non-MP proteases enabled differential processing of 
multiple peptide substrates by rADAM10 and 
rADAM17; lysates of wild-type and ADAM10 or 
ADAM17 knockout MEFs, ADAM10 knockout and 
ADAM10 restored MEFs, control and ADAM10 or 
ADAM17 silenced cancer cells; and control and 
ADAM10sa-inhibited cancer-cell and tumor-tissue 
lysates. The observed quantitative differences of 
substrate processing and related PrAMA indicated 
that 35% to 60% of the remaining enzyme activities in 
the lysates supplemented with non-MP protease 
inhibitors were mediated by ADAM10sa and 
ADAM17sa. The findings indicate that the selective 
suppression of non-MP proteases leads to decreases of 
the enzyme complexity, increases of ADAM10sa and 
ADAM17sa proportions and, consequently, increases 
of PrAMA accuracy while measuring the sheddase 
activities in cell and tissue lysates.  
The original PrAMA measured with a significant 
accuracy the individual MP activities in the limited 
complexity mixtures of the recombinant or 
cell-surface enzymes using the single Syntherror 
0.5/Sigmathreshold 1.0 parameter [35]. The 
high-sensitivity Syntherror parameter 0.5 could be 
also used in the modified PrAMA, and was able to 
quantify relatively small amounts of the recombinant 
(0.5 ng) and natural (0.5 µg lysate) ADAM10sa and 
ADAM17sa. However, using the original PrAMA 
Sigmathreshold (specificity) parameter 1.0, the 
modified-PrAMA could not measure with significant 
specificities ADAM10sa and ADAM17sa in cell and 
tissue lysates. This could be caused by higher 
complexities and variabilities of MP mixtures in cell 
and tissue lysates than on the cell surface. To 
accurately measure ADAM10sa and ADAM17sa in 
the lysates, we customized the maximal specificity 
PrAMA for each cell type or tumor-tissue specimen 
tested by performing the analysis via systematic 
increases of the specificity Sigmathreshold parameter. 
The systematic PrAMA showed simultaneous and 
gradual decreases of false-positive and increases of 
true-positive ADAM10sa and ADAM17sa 
proportions, and defined the applicable maximal 
specificity PrAMA. Thus modified PrAMA could 
measure mainly or exclusively true-positive 
ADAM10sa and ADAM17sa of the recombinant, 
MEF, cancer-cell and tumor-tissue enzymes using the 
specificity Sigmathreshold parameters 1.0 and 0.0, 1.7 
and 0.8, 1.4 and 1.4, and 1.4 and 0.8, respectively. 
Therefore, different amounts of ADAM10sa and 
ADAM17sa present in different cells and tissues could 
be measured with a significant accuracy using the 
PrAMA Syntherror/Sigmathreshold parameters 
0.5/1.4 to 0.5/1.7 and 0.5/0.8 to 0.5/1.4, respectively.  
More ADAM10 than ADAM17 protein was 
found expressed on the cell surface of NSCLC cells. 
Inversely, more ADAM17 than ADAM10 protein was 
found in the cell and tumor lysates comprising both 
cell-surface and cytoplasmic molecules. Correlating 
with the cell-surface protein expression, more 
ADAM10sa than ADAM17sa was found in the 
lysates. These findings confirm that the active forms 
of ADAM10 and ADAM17 are selectively expressed 
on the cell surface, where they perform sheddase 
activities, whereas the inactive pro-enzymes are 
primarily distributed inside of cells, where they are 
produced and/or temporarily stored. The findings 
also indicate that, in the presence of non-MP protease 
inhibitors, PrAMA selectively measured the 
cell-surface ADAM10sa and ADAM17sa in cell and 
tissue lysates.  
Testing recombinant enzymes, PrAMA- 
ADAM10sa specificity was found to be lower than 
PrAMA-ADAM17sa specificity. This might be caused 
by the higher specificity of PEPDAB cleavage sites for 
ADAM17sa than ADAM10sa. Inversely, when cell 
and tissue lysates were tested, PrAMA-ADAM10sa 
specificity was found to be higher than 
PrAMA-ADAM17sa specificity. These differences of 
PrAMA specificities for recombinant and natural 
enzymes might be caused by the high and similar 
levels of recombinant ADAM10sa and recombinant 
ADAM17sa, and high ADAM10sa and low 
ADAM17sa levels in the lysates. These findings and 
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considerations indicate that quantities of active 
enzymes could influence not only PrAMA sensitivity 
but also PrAMA specificity. 
In conclusion, we describe herein development 
of a PrAMA modification as a potential biomarker 
assay to specifically measure ADAM10sa and 
ADAM17sa in cell and tissue lysates by assessing their 
proteolytic activities in the presence of non-MP 
inhibitors and by maximizing the assay specificity via 
systematic changes of PrAMA-Sigmathreshold 
parameters. The modified PrAMA efficiently and 
with significant sensitivity and specificity measures 
the presence, absence, restoration and inhibition of 
ADAM10sa and/or ADAM17sa in cell and 
tumor-tissue lysates; and shows the essential 
characteristics of a robust high throughput clinically 
valuable assay that can specifically and accurately 
measure the sheddase activities in multiple specimens 
of solid tumors. The modified PrAMA is a unique 
biomarker assay. It is different from the original 
PrAMA that specifically measures live-cell MP 
activities in the absence of the protease inhibitors and 
using a single specificity parameter to infer the 
individual MPs from substrate-processing data [35]. 
Additionally, the modified PrAMA is especially 
different from and likely superior as a biomarker 
assay to standard gene- and protein-expression assays 
measuring without discrimination both inactive and 
active enzyme forms [21-34], sharply contrasting the 
modified PrAMA that selectively measures the 
specific enzyme proteolytic activities - the only 
enzyme forms directly relevant to cellular functions. 
Further studies are needed to determine the 
biomarker ability of the modified PrAMA.  
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